Denali Therapeutics Inc.

12.81
-0.93 (-6.77%)
At close: Apr 03, 2025, 1:03 PM

Denali Therapeutics Statistics

Share Statistics

Denali Therapeutics has 145.22M shares outstanding. The number of shares has increased by 1.83% in one year.

Shares Outstanding 145.22M
Shares Change (YoY) 1.83%
Shares Change (QoQ) 0.9%
Owned by Institutions (%) 75.5%
Shares Floating 125.71M
Failed to Deliver (FTD) Shares 7.28K
FTD / Avg. Volume 0.63%

Short Selling Information

The latest short interest is 7.97M, so 5.54% of the outstanding shares have been sold short.

Short Interest 7.97M
Short % of Shares Out 5.54%
Short % of Float 6.4%
Short Ratio (days to cover) 7.03

Valuation Ratios

The PE ratio is -7.93 and the forward PE ratio is -7.82. Denali Therapeutics's PEG ratio is -0.06.

PE Ratio -7.93
Forward PE -7.82
PS Ratio 0
Forward PS 2.3
PB Ratio 2.73
P/FCF Ratio -9.22
PEG Ratio -0.06
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Denali Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.46, with a Debt / Equity ratio of 0.03.

Current Ratio 8.46
Quick Ratio 8.46
Debt / Equity 0.03
Debt / EBITDA -0.09
Debt / FCF -0.12
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1M
Employee Count 422
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax -68K
Effective Tax Rate 0.02%

Stock Price Statistics

The stock price has increased by -28.96% in the last 52 weeks. The beta is 1.46, so Denali Therapeutics's price volatility has been higher than the market average.

Beta 1.46
52-Week Price Change -28.96%
50-Day Moving Average 18.51
200-Day Moving Average 23.1
Relative Strength Index (RSI) 39.68
Average Volume (20 Days) 1.16M

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -487.34M
Net Income -422.77M
EBITDA -487.34M
EBIT n/a
Earnings Per Share (EPS) -2.57
Full Income Statement

Balance Sheet

The company has 174.96M in cash and 42.29M in debt, giving a net cash position of 132.67M.

Cash & Cash Equivalents 174.96M
Total Debt 42.29M
Net Cash 132.67M
Retained Earnings -1.54B
Total Assets 1.37B
Working Capital 762.23M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -347.69M and capital expenditures -15.91M, giving a free cash flow of -363.61M.

Operating Cash Flow -347.69M
Capital Expenditures -15.91M
Free Cash Flow -363.61M
FCF Per Share -2.21
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

DNLI does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for DNLI is $32.5, which is 136.2% higher than the current price. The consensus rating is "Buy".

Price Target $32.5
Price Target Difference 136.2%
Analyst Consensus Buy
Analyst Count 17
Stock Forecasts

Scores

Altman Z-Score 5.74
Piotroski F-Score 2